Single User License
INR 133820
Site License
INR 267640
Corporate User License
INR 401460

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Liposarcoma-Pipeline Review, H1 2015

Liposarcoma-Pipeline Review, H1 2015

  Request for Sample Report

Executive Summary

Liposarcoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Liposarcoma-Pipeline Review, H1 2015', provides an overview of the Liposarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liposarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liposarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Liposarcoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Liposarcoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Liposarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Liposarcoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Liposarcoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Liposarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Liposarcoma Overview 6

Therapeutics Development 7

Pipeline Products for Liposarcoma-Overview 7

Pipeline Products for Liposarcoma-Comparative Analysis 8

Liposarcoma-Therapeutics under Development by Companies 9

Liposarcoma-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Liposarcoma-Products under Development by Companies 12

Liposarcoma-Companies Involved in Therapeutics Development 13

Daiichi Sankyo Company, Limited 13

Karyopharm Therapeutics, Inc. 14

Merck & Co., Inc. 15

Novartis AG 16

Pfizer Inc. 17

Pharma Mar, S.A. 18

Sanofi 19

Liposarcoma-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

cabazitaxel-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

efatutazone-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

everolimus-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

palbociclib-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

pembrolizumab-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

ribociclib-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

SAR-405838-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

selinexor-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

trabectedin-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Liposarcoma-Recent Pipeline Updates 59

Liposarcoma-Dormant Projects 83

Appendix 84

Methodology 84

Coverage 84

Secondary Research 84

Primary Research 84

Expert Panel Validation 84

Contact Us 84

Disclaimer 85

List of Tables

Number of Products under Development for Liposarcoma, H1 2015 7

Number of Products under Development for Liposarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Liposarcoma-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 13

Liposarcoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 14

Liposarcoma-Pipeline by Merck & Co., Inc., H1 2015 15

Liposarcoma-Pipeline by Novartis AG, H1 2015 16

Liposarcoma-Pipeline by Pfizer Inc., H1 2015 17

Liposarcoma-Pipeline by Pharma Mar, S.A., H1 2015 18

Liposarcoma-Pipeline by Sanofi, H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Stage and Target, H1 2015 22

Number of Products by Stage and Mechanism of Action, H1 2015 24

Number of Products by Stage and Route of Administration, H1 2015 26

Number of Products by Stage and Molecule Type, H1 2015 28

Liposarcoma Therapeutics-Recent Pipeline Updates, H1 2015 59

Liposarcoma-Dormant Projects, H1 2015 83

List of Figures

Number of Products under Development for Liposarcoma, H1 2015 7

Number of Products under Development for Liposarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Targets, H1 2015 21

Number of Products by Stage and Top 10 Targets, H1 2015 22

Number of Products by Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Top 10 Molecule Types, H1 2015 27

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Daiichi Sankyo Company, Limited

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Pharma Mar, S.A.


Liposarcoma Therapeutic Products under Development, Key Players in Liposarcoma Therapeutics, Liposarcoma Pipeline Overview, Liposarcoma Pipeline, Liposarcoma Pipeline Assessment

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]